Osaka Metropolitan University researchers developed a venetoclax-azacitidine drug combo for relapsed/refractory AML, improving survival rates with mild toxicity.
Researchers at Osaka Metropolitan University Graduate School of Medicine have developed a novel drug combination using venetoclax and azacitidine for relapsed/refractory acute myeloid leukemia (AML) patients, improving survival rates with mild toxicity. The combination therapy showed a 66.7% one-year survival rate compared to 27.3% for a control group. This novel treatment could lead to safer, more effective options for AML patients.
July 18, 2024
5 Articles